About NeoTherma Oncology
NeoTherma Oncology is a company based in Wichita (United States) founded in 2015. NeoTherma Oncology has raised $6 million across 2 funding rounds from investors including HHS and Gary Barnett. The company has 6 employees as of December 31, 2020. NeoTherma Oncology offers products and services including BloodFlow Guardian, CerebroZen, Endopeak, Nitric Boost Ultra, and GlucoFreedom. NeoTherma Oncology operates in a competitive market with competitors including ElmediX, Sensius, MagForce, Siva Therapeutics and MagHeals, among others.
- Headquarter Wichita, United States
- Employees 6 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Neotherma Oncology Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$6 M (USD)
in 2 rounds
-
Latest Funding Round
$65.75 K (USD), Grant
Aug 01, 2023
-
Investors
HHS
& 1 more
-
Employee Count
6
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NeoTherma Oncology
NeoTherma Oncology offers a comprehensive portfolio of products and services, including BloodFlow Guardian, CerebroZen, Endopeak, Nitric Boost Ultra, and GlucoFreedom.
Supports healthy blood pressure and cardiovascular function naturally.
Promotes hearing health and cognitive function with natural ingredients.
Enhances male vitality and energy levels through natural formulations.
Boosts energy and supports male health via improved blood flow.
Aids in maintaining healthy blood sugar levels naturally.
Supports brain health, memory, and focus with natural components.
Assists male sexual health and performance using herbal ingredients.
Helps reduce tinnitus symptoms and support brain health.
Supports weight loss and metabolism with natural tea-based elements.
Enhances cognitive function and memory through targeted ingredients.
Funding Insights of NeoTherma Oncology
NeoTherma Oncology has successfully raised a total of $6M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $65.75 thousand completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NeoTherma Oncology
NeoTherma Oncology has secured backing from 2 investors, including institutional and angel investors. Prominent investors backing the company include HHS and Gary Barnett.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
GB
Gary Barnett |
-
|
Locked | Locked | Locked |
Investor details for NeoTherma Oncology
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NeoTherma Oncology
Investment portfolio details for NeoTherma Oncology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NeoTherma Oncology
Detailed financials for NeoTherma Oncology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neotherma Oncology Comparisons
Peer comparison for NeoTherma Oncology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NeoTherma Oncology
NeoTherma Oncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ElmediX, Sensius, MagForce, Siva Therapeutics and MagHeals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of the device for treating pancreatic cancer
|
|
| Locked | Locked | Locked |
Developer of a hyperthermia system for cancer treatment. This system uses thermotherapy, a controlled heating process, to target tumors while preserving surrounding healthy tissue. The technology is designed to be integrated with existing radiotherapy workflows, offering improved clinical outcomes and enhanced quality of life for patients. The system is currently in development, with prototypes undergoing clinical trials. Future applications are planned for various cancer types.
|
|
| Locked | Locked | Locked |
Medical devices utilizing magnetic hyperthermia for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Gold nanoparticle hyperthermia technology for cancer therapy is developed.
|
|
| Locked | Locked | Locked |
Magnetic hyperthermia devices for non-invasive cancer treatment are provided.
|
Detailed competitors of NeoTherma Oncology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neotherma Oncology
Complete news archive for NeoTherma Oncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NeoTherma Oncology
NeoTherma Oncology was founded in 2015 and raised its 1st funding round 3 years after it was founded.
NeoTherma Oncology is headquartered in Wichita, United States. It is registered at Wichita, Kansas, United States.
NeoTherma Oncology is a funded company, having raised a total of $6M across 2 funding rounds to date.
As of Dec 31, 2020, the latest employee count at NeoTherma Oncology is 6.
NeoTherma Oncology was founded in 2015 in Wichita, United States, as a medical device company focused on oncology. The Vectron thermal oncology system is developed to deliver non-invasive, image-guided electromagnetic fields via integration with MRI suites. Local fever-range temperatures are generated in tumor tissue to enhance radiotherapy, chemotherapy, and immunotherapy outcomes. Operations center on advancing thermal treatments for solid tumors.
NeoTherma Oncology's top competitors include Sensius, MagHeals and Siva Therapeutics.
NeoTherma Oncology offers BloodFlow Guardian, CerebroZen, Endopeak, Nitric Boost Ultra, and 6 more products and services.
NeoTherma Oncology has 2 investors. Key investors include HHS, and Gary Barnett.